Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Radiother Oncol ; 60(1): 61-7, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11410305

RESUMO

PURPOSE: To evaluate in terms of probabilities of local-regional control and survival, as well as of treatment-related toxicity, results of radiosurgery for brain metastasis arising in previously irradiated territory. PATIENTS AND METHODS: Between January 1994 and March 2000, 54 consecutive patients presenting with 97 metastases relapsing after whole brain radiotherapy (WBRT) were treated with stereotactic radiotherapy. Median interval between the end of WBRT and radiosurgery was 9 months (range 2-70). Median age was 53 years (24-80), and median Karnofski performance status (KPS) 70 (60-100). Forty-seven patients had one radiosurgery, five had two and two had three. Median metastasis diameter and volume were 21 mm (6-59) and 1.2 cc (0.1-95.2), respectively. A Leksell stereotactic head frame (Leksell Model G, Elektra, Instrument, Tucker, GA) was applied under local anesthesia. Irradiation was delivered by a gantry mounted linear accelerator (linacs) (Saturne, General Electric). Median minimal dose delivered to the gross disease was 16.2 Gy (11.8-23), and median maximal dose 21.2 Gy (14- 42). RESULTS: Median follow-up was 9 months (1-57). Five metastases recurred. One- and 2-year metastasis local control rates were 91.3 and 84% and 1- and 2-year brain control rates were 65 and 57%, respectively. Six patients died of brain metastasis evolution, and three of leptomeningeal carcinomatosis. One- and 2-year overall survival rates were 31 and 28%, respectively. According to univariate analysis, KPS, RPA class, SIR score and interval between WBRT and radiosurgery were prognostic factors of overall survival and brain free-disease survival. According to multivariate analysis, RPA was an independent factor of overall survival and brain free-disease survival, and the interval between WBRT and radiosurgery longer than 14 months was associated with longer brain free-disease survival. Side effects were minimal, with only two cases of headaches and two of grade 2 alopecia. CONCLUSION: Salvage radiosurgery of metastasis recurring after whole brain irradiation is an effective and accurate treatment which could be proposed to patients with a KPS>70 and a primary tumour controlled or indolent. We recommend that a dose not exceeding 14 Gy should be delivered to an isodose representing 70% of the maximal dose since local control observed rate was similar to that previously published in literature with upper dose and side effects were minimal.


Assuntos
Neoplasias Encefálicas/secundário , Neoplasias Encefálicas/cirurgia , Radiocirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/radioterapia , Irradiação Craniana , Feminino , Seguimentos , Humanos , Avaliação de Estado de Karnofsky , Masculino , Pessoa de Meia-Idade , Terapia de Salvação
2.
Cancer Radiother ; 4 Suppl 1: 53s-66s, 2000 Nov.
Artigo em Francês | MEDLINE | ID: mdl-11194965

RESUMO

Gliomas are moderately radiosensitive. The main prognostic factors are the anatomicopathological type and grade of glioma, the performance status, age of the patient and the extent of the surgery. According to data from the literature, high-grade gliomas should be given 60 Gy in five weekly fractions of 1.7 to 2 Gy in a volume including tumor or tumor bed, edema and a 2- to 3-cm margin. A dose of 45 Gy would be sufficient for low-grade gliomas, according to the results of a recent randomized EORTC trial. Brachytherapy and radiosurgery techniques may be indicated in selected cases.


Assuntos
Astrocitoma/radioterapia , Neoplasias Encefálicas/radioterapia , Oligodendroglioma/radioterapia , Adulto , Astrocitoma/mortalidade , Astrocitoma/patologia , Braquiterapia/efeitos adversos , Braquiterapia/métodos , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/patologia , Humanos , Nêutrons/uso terapêutico , Oligodendroglioma/mortalidade , Oligodendroglioma/patologia , Fótons/uso terapêutico , Tolerância a Radiação , Radiossensibilizantes/uso terapêutico , Radiobiologia , Dosagem Radioterapêutica , Ensaios Clínicos Controlados Aleatórios como Assunto , Técnicas Estereotáxicas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa